Paxil ANDAs From Alphapharm, Sandoz Receive Final Approval From FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
TorPharm's exclusivity for paroxetine (GlaxoSmithKline's Paxil) comes to an end. FDA had tentatively approved both Alphapharm's and Sandoz' ANDAs.
You may also be interested in...
Andrx To Market Alphapharm Paxil Generic
Andrx will market Alphapharm's generic paroxetine (GlaxoSmithKline's Paxil) "shortly" under an agreement announced May 12
Andrx To Market Alphapharm Paxil Generic
Andrx will market Alphapharm's generic paroxetine (GlaxoSmithKline's Paxil) "shortly" under an agreement announced May 12
FDA Stands By Generic "Shared Exclusivity" Policy During Paxil Appeal
The agency will continue to award 180-day exclusivity to multiple ANDA filers "when applicable" while it appeals a ruling invalidating this approach for paroxetine generics. "Shared exclusivity" issues raised in the Paxil case could come up again if they are not resolved by the appeals court, FDA says.